Cited by 290Renin-Angiotensin System StudiesEstrogen and related hormone effectsEicosanoids and Hypertension Pharmacology

Estrogen regulation of angiotensin-converting enzyme mRNA

Gallagher, Patricia E., Li, Ping, Lenhart, John R., Chappell, Mark C., Brosnihan, K. Bridget·1999·Hypertension

Abstract

Abstract—Estrogen replacement therapy is cardioprotective in postmenopausal women; however, the precise molecular mechanisms for this modulation are not fully elucidated. We previously showed that chronic estrogen replacement therapy reduced angiotensin-converting enzyme (ACE) activity in tissue extracts and serum with an associated reduction in plasma angiotensin II. A reverse transcriptase–polymerase chain reaction assay was developed to determine whether estrogen treatment regulates tissue ACE mRNA concentration. Total RNA was isolated from kidney cortex, kidney medulla, lung, and aorta of ovariectomized Sprague-Dawley rats after 21 days of chronic 17β-estradiol replacement therapy (5 mg pellet per rat SC) or placebo. A marked decrease in densitometric intensity ratios of amplified ACE cDNA to elongation factor-1α control cDNA was observed in all tissues from placebo-treated rats compared with the estradiol-treated rats (renal cortex: 0.29±0.04 versus 0.14±0.02; renal medulla: 0.37±0.04 versus 0.24±0.03; lung: 4.49±0.37 versus 2.49±0.59; and aorta: 0.41±0.04 versus 0.29±0.02; all P<0.05). A comparable reduction in ACE activity was detected in tissue extracts from kidney cortex, kidney medulla, and lung of hormone-treated animals. Incubation of purified rat lung ACE with 1 or 10 μmol/L 17β-estradiol had no effect on enzyme activity. These results suggest that estrogen treatment regulates tissue ACE activity by reducing ACE mRNA concentrations. Thus, the beneficial cardiovascular effects of estrogen may be mediated in part by downregulation of ACE with a consequent reduction in the circulating levels of the vasoconstrictor angiotensin II, a decrease in the metabolism of the vasodilator bradykinin, and an increase in the production of the vasorelaxant angiotensin-(1–7).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.hyp.33.1.323

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Estrogen inhibits ACE expression and activity in rodent models.

    “Researchers have reported that both ACE expression and activity are inhibited by estrogen in rodent models [26-29].”
  • Plasma APP activity forms a continuous distribution in the general population, suggesting it is a complex quantitative trait likely influenced by multiple genetic loci and nongenetic factors.

    “Plasma APP activity has been shown to form a continuous distribution in the general population (Cyr et al. 2001), suggesting that plasma APP activity is a complex quantitative trait likely influenced by multiple genetic loci and nongenetic factors (e.g., smoking and hormone replacement therapy [Gallagher et al. 1999]).”

    From A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. (2005) · cites this paper as Gallagher et al. 1999

    Gallagher et al. is cited for hormone replacement therapy as a possible nongenetic influence on plasma APP activity. The Results section reports that hormone replacement lowered serum ACE activity in rats, but our copy does not address APP activity or establish an effect of hormone replacement on it. The continuous-distribution finding is attributed to Cyr et al., not Gallagher et al. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 54 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. PEPI Trial Working Group. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal woman. JAMA. 1995;273:199 -208.

Cited by

Sorted by citations

Authors
Gallagher, P. E., Li, P., Lenhart, J. R., Chappell, M. C., & Brosnihan, K. B.
Affiliations
Wake Forest University Health Sciences (US)
Venue
Hypertension
Published
1999-01
Volume
33
Issue
1
Pages
323-328
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2167128829
Cited by
290
References
54
Citations by year
2026: 3 · 2025: 6 · 2024: 3 · 2023: 9 · 2022: 8 · 2021: 14 · 2020: 12 · 2019: 14 · 2018: 11 · 2017: 9 · 2016: 7 · 2015: 4 · 2014: 9 · 2013: 9 · 2012: 7
FWCI
8.73
Type
journal article
Language
en
Open access
closed
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association (HL-56973)
  • National Institutes of Health (HL‐56973)
  • National Heart, Lung, and Blood Institute (R29HL056973, HL56973)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
estrogen, angiotensin-converting enzyme, estradiol, estrogen replacement therapy, angiotensin II, postmenopausal women, cardioprotection, renal cortex, renal medulla, lung, aorta, angiotensin-(1-7), bradykinin, ovariectomy
MeSH terms
Animals, Aorta, Estradiol, Female, Gene Expression Regulation, Humans, Kidney Cortex, Kidney Medulla, Peptidyl-Dipeptidase A, Lung, Muscle, Smooth, Vascular, Ovariectomy, RNA, Messenger, Transcription, Genetic, Estrogen Replacement Therapy, Rats, Sprague-Dawley, Reverse Transcriptase Polymerase Chain Reaction, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review